Welcome, this website is intended for all international healthcare professionals in uro-oncology. By clicking the link below you are declaring and confirming that you are a healthcare professional.

You are here

Treatment options for first-line therapies in advanced ccRCC

Commentary from Professor Susanne Osanto

10th April 2014

Dr. Motzer et al. reported a combined analysis of two open-label non-inferiority trials which compared pazopanib with sunitinib in a 1:1 ratio with respect to progression-free survival in renal-cell carcinoma. Thus, 1,110 patients with clear-cell, metastatic renal-cell carcinoma received a continuous dose of pazopanib or sunitinib in 6-week cycles. Progression-free survival (PFS) was the primary endpoint.

The authors concluded that pazopanib was non-inferior to sunitinib with respect to progression-free survival (hazard ratio for progression of disease or death from any cause, 1.05; 95% confidence interval [CI], 0.90 to 1.22) whereas overall survival (OS) was similar (hazard ratio for death with pazopanib, 0.91; 95% CI, 0.76 to 1.08). Despite critical comments on the statistical analysis of the trial, the data are supportive of pazopanib as an alternative for first-line treatment in metastatic clear cell kidney cancer next to sunitinib.


Pazopanib versus sunitinib in metastatic renal-cell carcinoma

Motzer RJ, Hutson TE, Cella D, Reeves J, Hawkins R, Guo J, Nathan P, Staehler M, de Souza P, Merchan JR, Boleti E, Fife K, Jin J, Jones R, Uemura H, De Giorgi U, Harmenberg U, Wang J, Sternberg CN, Deen K, McCann L, Hackshaw MD, Crescenzo R, Pandite LN, Choueiri TK.

N Engl J Med. 2013 Aug 22;369(8):722-31.


Subscribe to our E-Alert to keep up to date with the new items in the Resource Centre


URO ONCO is made possible by an unrestricted educational grant from:

The editorial independence of the resource centre is mandatory and recognized by the EAU and Elsevier.

The journal articles, videos and statements published on the resource centre have been selected independently and without influence from Elsevier, European Urology Editors or the sponsor and do not necessarily reflect their opinions or views.